In paediatric maligancies, HER2 alterations – principally copy number gains and gene over expression - was observed in 6% of all tumours in a paediatric pan-cancer cohort, predominatly in CNS tumours including Diffuse Hemishperic Gliomas (DHG), medulloblastoma, ependymoma, and a subset of neuroblastoma (14). Here, ERBB2 is linked to neoplasm.